Alireza Eghtedar

408 citations
18 papers · 260 · h-index 7

Impact in

  • Hematology top 5%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 10%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Hematology 11
    • Acute Myeloid Leukemia Research 6
    • Chronic Myeloid Leukemia Treatments 4
    • Hematopoietic Stem Cell Transplantation 3
  • Oncology 8
    • CAR-T cell therapy research 4
    • Polyomavirus and related diseases 2
Co-authors
Hagop M. Kantarjian (6 shared papers)Jörge E. Cortes (6 shared papers)Farhad Ravandi (5 shared papers)Gautam Borthakur (5 shared papers)Srđan Verstovšek (4 shared papers)Alessandra Ferrajoli (3 shared papers)Carol Bivins (2 shared papers)Zeev Estrov (2 shared papers)
Journals
Blood (8 papers)Cancer Research (2 papers)Journal of Clinical Oncology (1 paper)Journal of Pediatric Gastroenterology and Nutrition (1 paper)Transplantation and Cellular Therapy (1 paper)
Partner nations
United StatesAustraliaItaly

In The Last Decade

Alireza Eghtedar

15 papers receiving 257 citations

Peers

Alireza Eghtedar
Comparison fields: 5 of 40
  • Hematology 172
  • Genetics 120
  • Oncology 65
  • Rheumatology 34
  • Gastroenterology 7
Replace F.-X. Mahon with:
F.-X. Mahon France
Steven Richebourg France
Sivahari Prasad Gorantla Germany
R. Hehlmann Germany
Wenbin An China
Takashi Kumagai Japan
Fatima Zahra Jelloul United States
Francesco Iuliano Italy
Amritha Varshini Hanasoge Somasundara United States
Giulia Falconi Italy
Alireza Eghtedar relative to F.-X. Mahon France F.-X. Mahon's profile →
Citations per field
00.5×2×3×3.5×
F.-X. Mahon · 1×
Citations per year

Countries citing papers authored by Alireza Eghtedar

Since Specialization
Citations

This map shows the geographic impact of Alireza Eghtedar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alireza Eghtedar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alireza Eghtedar more than expected).

Fields of papers citing papers by Alireza Eghtedar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alireza Eghtedar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alireza Eghtedar. The network helps show where Alireza Eghtedar may publish in the future.

Co-authors

The 25 scholars most cited alongside Alireza Eghtedar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alireza Eghtedar Line = papers co-authored together Alireza Eghtedar links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Blood ·Alireza Eghtedar, Srđan Verstovšek, Zeev Estrov, Jan A. Burger, Jörge E. Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy Scherle, (unknown), Hagop M. Kantarjian, Farhad Ravandi
2012157
2
Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia ·Alireza Eghtedar, Hagop M. Kantarjian, Elias Jabbour, Susan O’Brien, Elizabeth M. Burton, Guillermo Garcia‐Manero, Srđan Verstovšek, Farhad Ravandi, Gautam Borthakur, Marina Konopleva, Alfonso Quintás‐Cardama, Jörge E. Cortes
201322
3
In Vitro Gluten Challenge Test for Celiac Disease Diagnosis
Journal of Pediatric Gastroenterology and Nutrition ·Maryam Khalesi, Seyed Ali Jafari, Mohammad Ali Kiani, Antonio Picarelli, Raffaele Borghini, Ramin Sadeghi, Alireza Eghtedar, Hosein Ayatollahi, Hamid Reza Kianifar
201517
4
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxide
Leukemia & lymphoma ·Alireza Eghtedar, I. Rodríguez, Hagop M. Kantarjian, Susan O’Brien, Naval Daver, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Tapan M. Kadia, Sherry Pierce, Jörge E. Cortes, Farhad Ravandi
201417
5
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia
American Journal of Hematology ·Alireza Eghtedar, Gautam Borthakur, Farhad Ravandi, Elias Jabbour, Jörge E. Cortes, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia‐Manero
20119
6
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation
Biology of Blood and Marrow Transplantation ·Mehdi Hamadani, Manoj Khanal, Kwang Woo Ahn, Carlos Litovich, Victor A. Chow, Alireza Eghtedar, Reem Karmali, Allison Winter, Timothy S. Fenske, Craig S. Sauter, Mohamed A. Kharfan‐Dabaja, Farrukh T. Awan
20207
7
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
Journal of Clinical Oncology ·Naval Daver, Abhishek Maiti, David A. Sallman, Gail J. Roboz, Melhem Solh, Filippo Milano, Stephen A. Strickland, Alireza Eghtedar, Steven B. Kanner, Guy Ledergor, Donna Marcy, Elizabeth Garner, Brian J. Francica, McKay Shaw, Kalin Bird, J Rattan, Enrique Zudaire, Socorro Portella, Pankit Vachhani, Jae H. Park
20246
8
Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)
Blood ·Alireza Eghtedar, Srđan Verstovšek, Jörge E. Cortes, Zeev Estrov, Jan A. Burger, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Robert Newton, Hagop M. Kantarjian, Farhad Ravandi
20105
9
A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
Blood ·Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu‐Waye Chu, Ravi Vij
20225
10
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
Blood ·William B. Donnellan, Ehab Atallah, Adam S. Asch, Manish R. Patel, Jay Yang, Alireza Eghtedar, Gautam Borthakur, Julie Charlton, Alexander MacDonald, Anna Korzeniowska, Elizabeth Sainsbury, Donald K. Strickland, Suzanne F. Jones, Philip Overend, Carrie A. Adelman, Giulia Fabbri, Jon Travers, Simon A. Smith, J. Elizabeth Pease, Jan Cosaert
20194
11
Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).
Blood ·Alireza Eghtedar, Hagop M. Kantarjian, Elias Jabbour, Susan O’Brien, Alfonso Quintás‐Cardama, Elizabeth M. Burton, Guillermo Garcia‐Manero, Srđan Verstovšek, Marina Konopleva, Jörge E. Cortes
20103
12
Abstract CT143: First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Correlative data
Cancer Research ·Muharrem Müftüoğlu, Enping Hong, Stephen A. Strickland, Alireza Eghtedar, Gary J. Schiller, Nosha Farhadfar, Ashish Bajel, Farhad Ravandi, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Brian S. Garrison, Timothy K. Lu, Kanya Rajangam, Michael Andreeff
20252
13
Abstract CT014: First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data
Cancer Research ·Stephen A. Strickland, Alireza Eghtedar, Nosha Farhadfar, Ashish Bajel, Farhad Ravandi, Rochelle Emery, Brian Garrison, Muharrem Müftüoğlu, Michael Andreeff, Kanya Rajangam, Gary J. Schiller
20252
14
Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting
PubMed ·Minoo Battiwalla, Ju-Hsien Chao, Tonya Cox, José C. Cruz, William B. Donnellan, Alireza Eghtedar, Suman Kambhampati, Shahbaz A. Malik, Michael B. Maris, Marcello Rotta, Frank T. Slovick, Aravind Ramakrishnan, Vikas Bhushan, Lindsay E. Sears, Casey Martin, Jared Holder, Angela G. Junglen, Navneet S. Majhail, Charles F. LeMaistre
20242
15
Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Blood ·Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stéphane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan M. Stein
20222
16
Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Blood ·Nosha Farhadfar, Stephen A. Strickland, Ashish Bajel, Alireza Eghtedar, Brian Garrison, Rochelle Emery, Kanya Rajangam, Gary J. Schiller, Farhad Ravandi
20250
17
Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention
Blood ·Zaid Al‐Kadhimi, Alireza Eghtedar, Zartash Gul, Wei Chen, Daryn Smith, Abhinav Deol, Muneer H. Abidi, Lawrence G. Lum, Divaya Bhutani, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
20130
18
Non-Myeloablative Hematopoietic Stem Cell Transplantation (NMA HSCT) Utilizing Low-Dose Total Body Irradiation (TBI) Plus Fludarabine (Flu): A Comparison of Single-Center Based Flu 150 mg/m2 Plus 400 Cgy TBI Versus Flu 90 mg/m2 and 200 Cgy TBI Containing Regimens
Transplantation and Cellular Therapy ·Alireza Eghtedar, Richard A. Nash, Ted Gooley, Tara Gregory, Jeffrey Matous, Luke Mountjoy, Julie A. Murphy, Marcello Rotta, Henning Schade, Michael Tees, Peter A. McSweeney, Michael Maris
20210

About Alireza Eghtedar

Alireza Eghtedar is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Immunology, having authored 18 papers that have together received 260 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (4 papers), CAR-T cell therapy research (4 papers), Hematopoietic Stem Cell Transplantation (3 papers), Acute Lymphoblastic Leukemia research (2 papers), Polyomavirus and related diseases (2 papers), Retinoids in leukemia and cellular processes (2 papers) and RNA Interference and Gene Delivery (2 papers). The work is most often cited by research in Hematology (172 citations), Genetics (120 citations), Oncology (65 citations), Rheumatology (34 citations) and Gastroenterology (7 citations). Alireza Eghtedar has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Gautam Borthakur, Srđan Verstovšek, Alessandra Ferrajoli, Carol Bivins, Zeev Estrov, Jan A. Burger and Stefan Faderl. Their work appears in journals such as Blood, Cancer Research, Journal of Clinical Oncology, Journal of Pediatric Gastroenterology and Nutrition and Transplantation and Cellular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F.-X. MahonBreakdown of academic impact, for papers by Steven RichebourgBreakdown of academic impact, for papers by Sivahari Prasad GorantlaBreakdown of academic impact, for papers by R. HehlmannBreakdown of academic impact, for papers by Wenbin AnBreakdown of academic impact, for papers by Takashi KumagaiBreakdown of academic impact, for papers by Fatima Zahra JelloulBreakdown of academic impact, for papers by Francesco IulianoBreakdown of academic impact, for papers by Amritha Varshini Hanasoge SomasundaraBreakdown of academic impact, for papers by Giulia Falconi